6:50 AM
 | 
Jan 16, 2019
 |  BC Extra  |  Financial News

Acceleron, Stemline price upsized follow-ons

Editor's Note: This article was updated on Jan 16, 2019 at 9:48 AM PST

Acceleron Pharma Inc. (NASDAQ:XLRN) and Stemline Therapeutics Inc. (NASDAQ:STML) have each priced upsized follow-ons, as one company prepares for key regulatory submissions and the other conducts its first product launch.

Acceleron said Wednesday that it raised $230 million through the sale of 5.3 million shares at $43. The price is a 7% discount to Acceleron's closing price of $46.44 on Monday, when it proposed after market hours to raise $200 million. Its shares slipped $2.52 to $43.92...

Read the full 361 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >